ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cash proceeds from sale of intangible product rights ($M) ($M)
Form 10-K Consolidated Statements of Cash Flows
Latest, FY2025
218
Period ended Dec 31, 2025
Change on a year earlier
-63.7%
601 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash proceeds from sale of intangible product rights ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 218 | -63.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 601 | -62.5% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 1,604 | +1,574.3% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 95.8 | -55.6% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 216 | – | Form 10-K (filed 2024-02-21) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cash proceeds from sale of intangible product rights ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/proceeds_sale_intang
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.